This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tashiro, H. Articles by Hedrick, L. Search for Related Content PubMed PubMed Citation Articles by Tashiro, H. Articles by Hedrick, L.

American Journal of Pathology, Vol 150, 177-185, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis

H Tashiro, C Isacson, R Levine, RJ Kurman, KR Cho and L Hedrick
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

Uterine serous carcinoma (USC) is an uncommon but aggressive type of endometrial cancer associated with rapid progression of disease and a poor prognosis. Both USC and its recently described putative precursor, endometrial intraepithelial carcinoma (EIC), demonstrate strong p53 overexpression by immunohistochemistry, suggesting alteration of the p53 gene in their pathogenesis. In the present study, we evaluated 21 USCs and 9 EICs for mutations in the p53 gene using direct sequence analysis and found that 90% of USCs and 78% of EICs contain mutations. Significantly, mutations were found in 3 cases of EIC without associated invasive carcinoma and identical mutations were detected in cases with synchronous USC and EIC. Strong p53 immunoreactivity was seen in the majority of USCs and EICs and correlated with p53 gene mutation, although lack of reactivity did not always indicate the absence of a gene mutation. Loss of heterozygosity of chromosome 17p was observed in 100% of USCs and in 43% of EICs, demonstrating that loss of the wild-type p53 allele occurs early in the development of serous carcinoma. Overall, our results reveal that p53 mutations are very common in USC and EIC. The presence of p53 gene mutations in EIC further suggests that p53 alteration plays an important role early in the pathogenesis of serous carcinoma, possibly accounting for its aggressive biological behavior.

This article has been cited by other articles:

				L. Jia, Y. Liu, X. Yi, A. Miron, C. P. Crum, B. Kong, and W. Zheng Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma Clin. Cancer Res., April 15, 2008; 14(8): 2263 - 2269. [Abstract] [Full Text] [PDF]

				O. Graesslin, S. Chantot-Bastaraud, M. Lorenzato, P. Birembaut, C. Quereux, and E. Darai Fluorescence in situ Hybridization and Immunohistochemical Analysis of p53 Expression in Endometrial Cancer: Prognostic Value and Relation to Ploidy Ann. Surg. Oncol., February 1, 2008; 15(2): 484 - 492. [Abstract] [Full Text] [PDF]

				S. C. Dowdy, S. Jiang, X. C. Zhou, X. Hou, F. Jin, K. C. Podratz, and S.-W. Jiang Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther., November 1, 2006; 5(11): 2767 - 2776. [Abstract] [Full Text] [PDF]

				M. B. Jones, A. P. Houwink, B. K. Freeman, T. M. Greenwood, J. M. Lafky, W. L. Lingle, A. Berchuck, G. L. Maxwell, K. C. Podratz, and N. J. Maihle The Granulin-Epithelin Precursor Is a Steroid-Regulated Growth Factor in Endometrical Cancer Reproductive Sciences, May 1, 2006; 13(4): 304 - 311. [Abstract] [PDF]

				K. A. Shedden, M. P. Kshirsagar, D. R. Schwartz, R. Wu, H. Yu, D. E. Misek, S. Hanash, H. Katabuchi, L. H. Ellenson, E. R. Fearon, et al. Histologic Type, Organ of Origin, and Wnt Pathway Status: Effect on Gene Expression in Ovarian and Uterine Carcinomas Clin. Cancer Res., March 15, 2005; 11(6): 2123 - 2131. [Abstract] [Full Text] [PDF]

				J. Planaguma, M. Diaz-Fuertes, A. Gil-Moreno, M. Abal, M. Monge, A. Garcia, T. Baro, T. M. Thomson, J. Xercavins, F. Alameda, et al. A Differential Gene Expression Profile Reveals Overexpression of RUNX1/AML1 in Invasive Endometrioid Carcinoma Cancer Res., December 15, 2004; 64(24): 8846 - 8853. [Abstract] [Full Text] [PDF]

				S. X. Liang, S. K. Chambers, L. Cheng, S. Zhang, Y. Zhou, and W. Zheng Endometrial Glandular Dysplasia: A Putative Precursor Lesion of Uterine Papillary Serous Carcinoma. Part II: Molecular Features International Journal of Surgical Pathology, October 1, 2004; 12(4): 319 - 331. [Abstract] [PDF]

				Y.-T. Jeon, S. Kang, D.-H. Kang, K.-Y. Yoo, I.-A. Park, Y.-J. Bang, J. W. Kim, N.-H. Park, S.-B. Kang, H.-P. Lee, et al. Cyclooxygenase-2 and p53 Expressions in Endometrial Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1538 - 1542. [Abstract] [Full Text] [PDF]

				B. M. Slomovitz, R. R. Broaddus, T. W. Burke, N. Sneige, P. T. Soliman, W. Wu, C. C. Sun, M. F. Munsell, D. M. Gershenson, and K. H. Lu Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma J. Clin. Oncol., August 1, 2004; 22(15): 3126 - 3132. [Abstract] [Full Text] [PDF]

				W. Zheng, S. X. Liang, H. Yu, T. Rutherford, S. K. Chambers, and P. E. Schwartz Endometrial Glandular Dysplasia: A Newly Defined Precursor Lesion of Uterine Papillary Serous Carcinoma. Part I: Morphologic Features International Journal of Surgical Pathology, July 1, 2004; 12(3): 207 - 223. [Abstract] [PDF]

				M. Saegusa, M. Hashimura, T. Kuwata, M. Hamano, and I. Okayasu {beta}-Catenin Simultaneously Induces Activation of the p53-p21WAF1 Pathway and Overexpression of Cyclin D1 during Squamous Differentiation of Endometrial Carcinoma Cells Am. J. Pathol., May 1, 2004; 164(5): 1739 - 1749. [Abstract] [Full Text] [PDF]

				F.-S. Liu, J.-T. Dong, J.-T. Chen, Y.-T. Hsieh, E. S.-C. Ho, M.-J. Hung, C.-H. Lu, and L.-C. Chiou KAI1 Metastasis Suppressor Protein Is Down-Regulated during the Progression of Human Endometrial Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1393 - 1398. [Abstract] [Full Text] [PDF]

				G. L. Maxwell, J. I. Risinger, K. A. Hayes, A. A. Alvarez, R. K. Dodge, J. C. Barrett, and A. Berchuck Racial Disparity in the Frequency of PTEN Mutations, but not Microsatellite Instability, in Advanced Endometrial Cancers Clin. Cancer Res., August 1, 2000; 6(8): 2999 - 3005. [Abstract] [Full Text]

				I. U. Ali Gatekeeper for Endometrium: the PTEN Tumor Suppressor Gene J Natl Cancer Inst, June 7, 2000; 92(11): 861 - 863. [Full Text] [PDF]

				I. U. Ali, L. M. Schriml, and M. Dean Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity J Natl Cancer Inst, November 17, 1999; 91(22): 1922 - 1932. [Abstract] [Full Text] [PDF]

				H. B. Salvesen, O. E. Iversen, and L. A. Akslen Prognostic Significance of Angiogenesis and Ki-67, p53, and p21 Expression: A Population-Based Endometrial Carcinoma Study J. Clin. Oncol., May 1, 1999; 17(5): 1382 - 1382. [Abstract] [Full Text] [PDF]

				R. J. Rayanade, M. I. Ndubuisi, J. D. Etlinger, and P. B. Sehgal Regulation of IL-6 Signaling by p53: STAT3- and STAT5-Masking in p53-Val135-Containing Human Hepatoma Hep3B Cell Lines J. Immunol., July 1, 1998; 161(1): 325 - 334. [Abstract] [Full Text] [PDF]